Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivabradine and Beta-blockers in Heart Failure with ICD
NCT01868880Phase 4Withdrawn
- Sponsor
- Policlinico Casilino
- Start
- Feb 2016
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ivabradine in heart failure (HF) (2 arms), sponsored by Policlinico Casilino. Primary endpoint: Right ventricular pacing percentage increase > 50% or Cardiovascular death or Heart failure decompensation or Crossover due to worsening heart failure at 12 months. Planned start Feb 2016; status: withdrawn.
02
Drugs
ivabradine
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT01868880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01868880.